MacroGenics Faces FDA Partial Hold on Key Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MGNX?
Source: seekingalpha
- FDA Clinical Hold: MacroGenics announced a partial clinical hold on its mid-stage trial LINNET for its lead asset lorigerlimab, causing the company's stock to drop approximately 18% in premarket trading.
- Safety Event Reporting: The hold was initiated by the FDA following reports of safety events in four patients treated with lorigerlimab, including Grade 4 thrombocytopenia, myocarditis, and neutropenia, with one case resulting in a Grade 5 septic shock.
- Trial Participation Status: So far, 41 subjects have received 6 mg/kg of lorigerlimab every three weeks in the LINNET trial, and while new patient enrollment is halted, existing patients will continue to receive the experimental therapy.
- Market Reaction: The FDA's intervention introduces uncertainty regarding the progress of MacroGenics' clinical trials, which could impact the company's future drug approval plans and overall market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MGNX
Wall Street analysts forecast MGNX stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 1.990
Low
2.00
Averages
3.00
High
4.00
Current: 1.990
Low
2.00
Averages
3.00
High
4.00
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
MacroGenics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: MacroGenics will participate in several investor conferences in March in Boston and Miami, with CEO Eric Risser scheduled to deliver a hybrid presentation at the TD Cowen conference on March 3, which is expected to attract investor interest and enhance the company's visibility.
- One-on-One Meeting Opportunities: Management will engage in one-on-one meetings at all conferences, providing potential investors with an in-depth understanding of the company's strategy and product pipeline, which could facilitate future investment decisions.
- Webcast Availability: All presentations will be accessible via live webcasts on the company's investor relations website, with a 30-day replay available, enhancing transparency and providing a follow-up opportunity for investors who cannot attend live.
- Technological Platform Advantage: MacroGenics focuses on developing innovative monoclonal antibody therapies, and its advanced technology platforms and protein engineering expertise have led to strategic collaborations with several global pharmaceutical and biotechnology companies, further solidifying its market position in cancer treatment.
See More
MacroGenics Faces FDA Partial Hold on Key Clinical Trial
- FDA Clinical Hold: MacroGenics announced a partial clinical hold on its mid-stage trial LINNET for its lead asset lorigerlimab, causing the company's stock to drop approximately 18% in premarket trading.
- Safety Event Reporting: The hold was initiated by the FDA following reports of safety events in four patients treated with lorigerlimab, including Grade 4 thrombocytopenia, myocarditis, and neutropenia, with one case resulting in a Grade 5 septic shock.
- Trial Participation Status: So far, 41 subjects have received 6 mg/kg of lorigerlimab every three weeks in the LINNET trial, and while new patient enrollment is halted, existing patients will continue to receive the experimental therapy.
- Market Reaction: The FDA's intervention introduces uncertainty regarding the progress of MacroGenics' clinical trials, which could impact the company's future drug approval plans and overall market performance.
See More
MacroGenics Faces Partial Clinical Hold on LINNET Study
- Clinical Hold Imposed: MacroGenics' stock fell 18.29% in premarket trading on Tuesday following the FDA's announcement of a partial clinical hold on its LINNET study, indicating market concerns over safety issues.
- Safety Events Reported: The hold was triggered by safety events affecting four patients, including two cases of Grade 4 thrombocytopenia, one case of Grade 4 myocarditis, and one case of Grade 4 neutropenia with concurrent septic shock, culminating in one patient death, highlighting the drug's potential risks.
- Participant Status: To date, 41 participants have been dosed at 6 mg/kg every three weeks, with the primary endpoint being the objective response rate; the pause in new participant enrollment may impact the study's timeline and outcomes.
- Management's Commitment: CEO Eric Risser emphasized that patient safety is the company's top priority and that MacroGenics is fully committed to working closely with the FDA to resolve the clinical hold and resume study enrollment as soon as possible.
See More
MacroGenics Faces Partial Clinical Hold on LINNET Study
- FDA Clinical Hold: The FDA has placed a partial clinical hold on MacroGenics' LINNET study, halting new patient enrollment while allowing the current 41 participants to continue treatment, which may hinder the company's research progress in gynecologic cancers.
- Impact of Safety Events: The hold was initiated due to reported safety events in the LINNET trial, including three patients experiencing Grade 4 (life-threatening) events and one Grade 5 (fatal) event, potentially damaging the company's reputation and future funding prospects.
- Study Design and Objectives: The LINNET study aims to evaluate the efficacy of lorigerlimab in platinum-resistant ovarian cancer patients who have undergone up to three prior therapies, with a potential expansion to enroll an additional 20 patients if predefined activity thresholds are met, but the current hold will delay this process.
- Market Reaction and Stock Volatility: Following the news, MGNX's stock plummeted 8.57% to $1.60, reflecting investor anxiety over clinical progress, with the stock trading between $0.99 and $2.78 over the past year, indicating market uncertainty regarding the company's future.
See More
MacroGenics Faces Partial Clinical Hold on LINNET Study
- Clinical Hold Imposed: The FDA has placed a partial clinical hold on MacroGenics' LINNET study, preventing new patient enrollment while allowing current participants to continue treatment, which may hinder the company's clinical progress and market confidence.
- Safety Events Raise Concerns: The hold was prompted by serious safety events in four patients, including two cases of Grade 4 thrombocytopenia and one case of Grade 4 myocarditis, indicating potential risks of the drug in specific patient populations, which could affect future study designs and regulatory approvals.
- Study Design Overview: The LINNET study evaluates the efficacy of lorigerlimab in ovarian cancer patients who have undergone up to three prior therapies, with the potential to expand enrollment if initial results meet predefined thresholds, making the success of this strategy critical for the company's future market performance.
- Company Commitment and Future Plans: MacroGenics' CEO stated that the company is fully committed to working with the FDA to resolve the hold and resume enrollment as soon as possible, aiming to rebuild investor confidence and advance its long-term strategy in cancer drug development.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
MacroGenics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: MacroGenics will participate in several investor conferences in March in Boston and Miami, with CEO Eric Risser scheduled to deliver a hybrid presentation at the TD Cowen conference on March 3, which is expected to attract investor interest and enhance the company's visibility.
- One-on-One Meeting Opportunities: Management will engage in one-on-one meetings at all conferences, providing potential investors with an in-depth understanding of the company's strategy and product pipeline, which could facilitate future investment decisions.
- Webcast Availability: All presentations will be accessible via live webcasts on the company's investor relations website, with a 30-day replay available, enhancing transparency and providing a follow-up opportunity for investors who cannot attend live.
- Technological Platform Advantage: MacroGenics focuses on developing innovative monoclonal antibody therapies, and its advanced technology platforms and protein engineering expertise have led to strategic collaborations with several global pharmaceutical and biotechnology companies, further solidifying its market position in cancer treatment.
See More
MacroGenics Faces FDA Partial Hold on Key Clinical Trial
- FDA Clinical Hold: MacroGenics announced a partial clinical hold on its mid-stage trial LINNET for its lead asset lorigerlimab, causing the company's stock to drop approximately 18% in premarket trading.
- Safety Event Reporting: The hold was initiated by the FDA following reports of safety events in four patients treated with lorigerlimab, including Grade 4 thrombocytopenia, myocarditis, and neutropenia, with one case resulting in a Grade 5 septic shock.
- Trial Participation Status: So far, 41 subjects have received 6 mg/kg of lorigerlimab every three weeks in the LINNET trial, and while new patient enrollment is halted, existing patients will continue to receive the experimental therapy.
- Market Reaction: The FDA's intervention introduces uncertainty regarding the progress of MacroGenics' clinical trials, which could impact the company's future drug approval plans and overall market performance.
See More
MacroGenics Faces Partial Clinical Hold on LINNET Study
- Clinical Hold Imposed: MacroGenics' stock fell 18.29% in premarket trading on Tuesday following the FDA's announcement of a partial clinical hold on its LINNET study, indicating market concerns over safety issues.
- Safety Events Reported: The hold was triggered by safety events affecting four patients, including two cases of Grade 4 thrombocytopenia, one case of Grade 4 myocarditis, and one case of Grade 4 neutropenia with concurrent septic shock, culminating in one patient death, highlighting the drug's potential risks.
- Participant Status: To date, 41 participants have been dosed at 6 mg/kg every three weeks, with the primary endpoint being the objective response rate; the pause in new participant enrollment may impact the study's timeline and outcomes.
- Management's Commitment: CEO Eric Risser emphasized that patient safety is the company's top priority and that MacroGenics is fully committed to working closely with the FDA to resolve the clinical hold and resume study enrollment as soon as possible.
See More
MacroGenics Faces Partial Clinical Hold on LINNET Study
- FDA Clinical Hold: The FDA has placed a partial clinical hold on MacroGenics' LINNET study, halting new patient enrollment while allowing the current 41 participants to continue treatment, which may hinder the company's research progress in gynecologic cancers.
- Impact of Safety Events: The hold was initiated due to reported safety events in the LINNET trial, including three patients experiencing Grade 4 (life-threatening) events and one Grade 5 (fatal) event, potentially damaging the company's reputation and future funding prospects.
- Study Design and Objectives: The LINNET study aims to evaluate the efficacy of lorigerlimab in platinum-resistant ovarian cancer patients who have undergone up to three prior therapies, with a potential expansion to enroll an additional 20 patients if predefined activity thresholds are met, but the current hold will delay this process.
- Market Reaction and Stock Volatility: Following the news, MGNX's stock plummeted 8.57% to $1.60, reflecting investor anxiety over clinical progress, with the stock trading between $0.99 and $2.78 over the past year, indicating market uncertainty regarding the company's future.
See More
MacroGenics Faces Partial Clinical Hold on LINNET Study
- Clinical Hold Imposed: The FDA has placed a partial clinical hold on MacroGenics' LINNET study, preventing new patient enrollment while allowing current participants to continue treatment, which may hinder the company's clinical progress and market confidence.
- Safety Events Raise Concerns: The hold was prompted by serious safety events in four patients, including two cases of Grade 4 thrombocytopenia and one case of Grade 4 myocarditis, indicating potential risks of the drug in specific patient populations, which could affect future study designs and regulatory approvals.
- Study Design Overview: The LINNET study evaluates the efficacy of lorigerlimab in ovarian cancer patients who have undergone up to three prior therapies, with the potential to expand enrollment if initial results meet predefined thresholds, making the success of this strategy critical for the company's future market performance.
- Company Commitment and Future Plans: MacroGenics' CEO stated that the company is fully committed to working with the FDA to resolve the hold and resume enrollment as soon as possible, aiming to rebuild investor confidence and advance its long-term strategy in cancer drug development.
See More
